scout
|Videos|January 7, 2016

Dr. Formenti on Combining Radiotherapy With Immunotherapy in NSCLC

Silvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).

Silvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).

Previous studies investigating anti—CTLA-4 monoclonal antibodies had failed to demonstrate a significant impact in NSCLC, says Formenti. However, when ipilimumab was combined with radiotherapy a 33% objective response rate was demonstrated in patients with NSCLC.

Patients who responded compared to those who did not had some evidence of immunization, as demonstrated by circulating lymphocytes, says Formenti.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME